Fig. 3From: Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthmaConstruction of the trivalent bispecific IL-5-HSA Nb. A The binding activity of HSA Nb towards human albumin and cynomolgus monkey albumin (CSA) at pH 5.5 and pH 7.4 was determined by ELISA. B The structure of trivalent bispecific IL-5-HSA Nb. C-D The affinity of trivalent IL-5-HSA Nb and Nucala analogue to IL-5 was detected by FortebioBack to article page